Waldenstrom Macroglobulinemia — Trials

Waldenstrom Macroglobulinemia — Trials · CancerIndex

Clinical trials

Registered studies

308 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 59
Recruiting: 26
Ph III recruiting: 2
Growth YoY: —
Industry share: 39%
Top sponsor: Christian Buske
Termination share: 30.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (53)

clinicaltrialsPublishedShowing 301–308 of 308 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00107614	DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients	terminated	Phase 2	12	University of ArkansasOTHER	1	Aug 26, 2011	clinicaltrials
NCT00273936	Trial of AVN-944 in Patients With Advanced Hematologic Malignancies	completed	Phase 1	72	Vertex Pharmaceuticals IncorporatedINDUSTRY	1	Aug 4, 2011	clinicaltrials